Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227†

Ruxrungtham, KPedro, RJLatiff, GHConradie, FDomingo, PLupo, SPumpradit, WVingerhoets, JHPeeters, MPeeters, IKakuda, TNDe Smedt, GWoodfall, Bon behalf of the TMC125-C227 study group2024-05-232024-05-232008-11-27https://doi.org/10.1111/j.1468-1293.2008.00644.xhttps://repositorio.huesped.org.ar/handle/123456789/1422Fil: Ruxrungtham K. HIV-NAT, Thai Red Cross AIDS Research Center and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok; ThailandHIV-NAT, Thai Red Cross AIDS Research Center and Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailanapplication/pdfopenAccessImpact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227†Articulo